Group One Trading
QNCX icon

Group One Trading’s Quince Therapeutics QNCX Stock Holding History

Group One Trading’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$150 – 8157
2023
Q2 		$150 Hold
1
– – ﹤0.01% 7490
2023
Q1 		$156 Sell
1
-31
-97% -$6.07K ﹤0.01% 7010
2022
Q4 		$4.01K Sell
32
-457
-93% -$76.4K ﹤0.01% 6426
2022
Q3 		$130K Sell
489
-23
-4% -$8.76K ﹤0.01% 4529
2022
Q2 		$227K Sell
512
-133
-21% -$94K ﹤0.01% 4170
2022
Q1 		$799K Buy
645
+557
+633% +$758K ﹤0.01% 3317
2021
Q4 		$221K Sell
88
-98
-53% -$598K ﹤0.01% 4979
2021
Q3 		$3.4M Buy
186
+158
+564% +$2.51M ﹤0.01% 2104
2021
Q2 		$292K Buy
28
+25
+833% +$210K ﹤0.01% 4815
2021
Q1 		$22K Buy
+3
New +$21.6K ﹤0.01% 6724

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading's QNCX Position: Q1 2026 in Review

Group One Trading sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 702 shares — an estimated $141K sold.

Group One Trading first reported a position in QNCX in Q4 2020 and held it in 11 quarters. The position peaked at $647K in Q1 2022. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Group One Trading reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 702 Quince Therapeutics shares in Q1 2026, an estimated $141K.
  • Group One Trading first reported a position in Quince Therapeutics in Q4 2020 and held it in 11 quarters.
  • Group One Trading's Quince Therapeutics position peaked at $647K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.